{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:37:08Z","timestamp":1792661828151,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To study the relationship between gene expression profile subclass and clinical features in a multicenter cohort of patients with uveal melanoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective, multicenter study was undertaken with patients entered from nine major ocular oncology centers from across the United States. Eligible patients had uveal melanoma and underwent I-125 plaque brachytherapy with concurrent tumor biopsy with gene expression profile testing between January 1, 2010, and October 28, 2014. Data were collected regarding patient demographics, baseline tumor clinical features, and gene expression profile results. Statistical analyses were performed using the Fisher's exact test, Wilcoxon rank-sum test, Kruskal\u2013Wallis test, and proportional-odds cumulative logit modeling.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Inclusion criteria were met for 379 patients. Gene expression profile class divided the cohort into two main groups, Class 1 (n = 263) and Class 2 (n = 113). Class 1 tumors were further subdivided into Class 1a (n = 186) and Class 1b (n = 77). The differences between Class 1 and Class 2 tumors were similar to previous studies, except the finding of Class 2 tumors being more likely to have associated exudative retinal detachment (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). There was no statistically significant difference between Class 1 and Class 2 tumors based on the presence of lipofuscin, drusen, or subretinal fluid. Class 1a tumor patients, compared with Class 1b, were significantly older (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.034). Class 2 tumors, when compared with Class 1b, were associated with increasing patient age (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), larger tumor height (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.010), ciliary body involvement (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001), exudative retinal detachment (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.024), and anterior tumor location (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). When the tumors were grouped into Collaborative Ocular Melanoma Study size categories, increasing tumor size category was significantly associated with Class 2 status: 6% of small tumors, 32% of medium tumors, and 53% of large tumors were Class 2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In a multi-institutional setting, we found that the only significant difference in clinical features between Class 1a and Class 1b tumors was that patients with Class 1a tumors were older at the time of diagnosis. We also found that Class 1a and Class 1b have clinical features distinct from Class 2 tumors. The distribution of the gene expression profile subclasses among the size groups was similar to reported time-to-metastasis data among the same size groupings. Our clinical findings support the current molecular classification-based survival data previously reported in uveal melanoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002113","type":"journal-article","created":{"date-parts":[[2018,3,25]],"date-time":"2018-03-25T20:37:29Z","timestamp":1522010249000},"page":"1154-1164","source":"Crossref","is-referenced-by-count":17,"title":["RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA"],"prefix":"10.1097","volume":"39","author":[{"given":"Duncan","family":"Berry","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Duke University, Durham, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Seider","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University, Durham, North Carolina;"},{"name":"The Permanente Medical Group, San Francisco, California, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Stinnett","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University, Durham, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University, Durham, North Carolina;"},{"name":"Department of Radiation Oncology, Duke University, Durham, North Carolina;"},{"name":"Byers Eye Institute, Stanford University, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Schefler","sequence":"additional","affiliation":[{"name":"Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas;"},{"name":"Retina Consultants of Houston, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Ocular Oncology Study Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9394(14)77914-0","article-title":"Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology","volume":"96","author":"McLean","year":"1983","journal-title":"Am J Ophthalmol"},{"key":"R3-20230816","first-page":"12","article-title":"Malignant melanotic tumours of the eye: a study of histologic types in 111 cases","volume":"36","author":"GR","year":"1931","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"R4-20230816","first-page":"745","article-title":"Histopathology, morphometry, and nuclear DNA content of iris melanocytic lesions","volume":"36","author":"Grossniklaus","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0161-6420(94)31184-5","article-title":"Mean of the ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas","volume":"101","author":"Pe'er","year":"1994","journal-title":"Ophthalmology"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-6420(93)31470-3","article-title":"The prognostic value of tumor blood vessel morphology in primary uveal melanoma","volume":"100","author":"Folberg","year":"1993","journal-title":"Ophthalmology"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","article-title":"Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes","volume":"127","author":"Shields","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaophthalmol.2014.5395","article-title":"International validation of the American Joint Committee on Cancer's 7th Edition classification of uveal melanoma","volume":"133","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0161-6420(95)30864-0","article-title":"Risk factors for growth and metastasis of small choroidal melanocytic lesions","volume":"102","author":"Shields","year":"1995","journal-title":"Ophthalmology"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0140-6736(96)90736-9","article-title":"Prognostic implications of monosomy 3 in uveal melanoma","volume":"347","author":"Prescher","year":"1996","journal-title":"Lancet"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/1097-0142(19930201)71:3<811::AID-CNCR2820710325>3.0.CO;2-F","article-title":"Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q","volume":"71","author":"Horsman","year":"1993","journal-title":"Cancer"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/gcc.2870020307","article-title":"Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8","volume":"2","author":"Sisley","year":"1990","journal-title":"Genes Chromosomes Cancer"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1167\/iovs.08-3165","article-title":"Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death","volume":"50","author":"Damato","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1167\/iovs.02-0159","article-title":"Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival","volume":"44","author":"Scholes","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1167\/iovs.04-1460","article-title":"Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients","volume":"46","author":"Kilic","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<354::AID-CNCR20>3.0.CO;2-R","article-title":"Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma","volume":"83","author":"White","year":"1998","journal-title":"Cancer"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","article-title":"Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death","volume":"64","author":"Onken","year":"2004","journal-title":"Cancer Res"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2015.11.019","article-title":"Independent prognostic significance of gene expression profile class and largest basal diameter of posterior uveal melanomas","volume":"162","author":"Correa","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00417-016-3305-2","article-title":"Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height","volume":"254","author":"Gupta","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3928\/23258160-20150323-06","article-title":"Gene expression profiling and regression rate of irradiated uveal melanomas","volume":"46","author":"Rao","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1167\/iovs.13-13381","article-title":"Relationship between rate of posterior uveal melanoma flattening following plaque radiotherapy and gene expression profile class of tumor cells","volume":"55","author":"Correa","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ajo.2012.02.022","article-title":"Uveal melanoma: molecular pattern, clinical features, and radiation response","volume":"154","author":"Chappell","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/jamaophthalmol.2016.0913","article-title":"Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma","volume":"134","author":"Walter","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.ophtha.2017.04.013","article-title":"Association between tumor regression rate and gene expression profile following I-125 plaque radiotherapy for uveal melanoma","volume":"124","author":"Mruthyunjaya","year":"2017","journal-title":"Ophthalmology"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0161-6420(02)01277-0","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19","volume":"109","author":"Jampol","year":"2002","journal-title":"Ophthalmology"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28","volume":"124","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1001\/archopht.120.12.1665","article-title":"Evidence-based estimates of outcome in patients irradiated for intraocular melanoma","volume":"120","author":"Gragoudas","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","article-title":"Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes","volume":"134","author":"Decatur","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R33-20230816","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/eye.2012.253","article-title":"Inflammation in uveal melanoma","volume":"27","author":"Bronkhorst","year":"2013","journal-title":"Eye"},{"key":"R34-20230816","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/IAE.0b013e318239e299","article-title":"Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma","volume":"32","author":"Dunavoelgyi","year":"2012","journal-title":"Retina"},{"key":"R35-20230816","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3892\/mco.2014.247","article-title":"Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: a meta-analysis","volume":"2","author":"Yang","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"R36-20230816","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/archopht.118.3.360","article-title":"Combination of clinical factors predictive of growth of small choroidal melanocytic tumors","volume":"118","author":"Shields","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R37-20230816","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ophtha.2006.01.053","article-title":"Small choroidal melanocytic lesions: features predictive of growth","volume":"113","author":"Singh","year":"2006","journal-title":"Ophthalmology"},{"key":"R38-20230816","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"},{"key":"R39-20230816","doi-asserted-by":"crossref","first-page":"59209","DOI":"10.18632\/oncotarget.10962","article-title":"Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas","volume":"7","author":"Field","year":"2016","journal-title":"Oncotarget"},{"key":"R40-20230816","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0161-6420(94)31274-7","article-title":"Natural history of indeterminate pigmented choroidal tumors","volume":"101","author":"Butler","year":"1994","journal-title":"Ophthalmology"},{"key":"R41-20230816","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archopht.1997.01100160707007","article-title":"Factors predictive of growth and treatment of small choroidal melanoma: COMS report no. 5. The Collaborative Ocular Melanoma Study Group","volume":"115","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"R42-20230816","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/archophthalmol.2009.151","article-title":"Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases","volume":"127","author":"Shields","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R43-20230816","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report no. 26","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R44-20230816","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.2012.45.2771","article-title":"Staging of ciliary body and choroidal melanomas based on anatomic extent","volume":"31","author":"Kujala","year":"2013","journal-title":"J Clin Oncol"},{"key":"R45-20230816","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1167\/iovs.16-19654","article-title":"External validation of the Liverpool uveal melanoma prognosticator online","volume":"57","author":"DeParis","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R46-20230816","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1504\/IJBET.2012.045355","article-title":"Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis","volume":"8","author":"Eleuteri","year":"2012","journal-title":"Int J Biomed Eng Tech"},{"key":"R47-20230816","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1167\/iovs.16-20212","article-title":"The prognostic value of AJCC staging in uveal melanoma is enhanced by adding chromosome 3 and 8q status","volume":"58","author":"Dogrusoz","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201906000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:22:21Z","timestamp":1692231741000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201906000-00018"}},"subtitle":["A Multi-institutional Study"],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002113","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}